## BRAWN BIOTECH LIMITED (formarly known as Brawn Pharmaceuticals Limited) REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024

Part I	art I (Rs in Lac					(Rs in Lacs)	
Statement of standalone Unaudited Results for the Quarter ended 31 December 2013							
S. No.	PARTICULARS	Quarter Ended 31.12.2013 Unaudited	Quarter Ended 30.09.2013 Unaudited	Quarter Ended 31.12.2012 Unaudited	Nine Months ended 31.12.2013 Unaudited	Nine Months ended 31.12.2012 Unaudited	Year Ended 31.03.2013 Audited
1	Income from Operations						
a.	Net Sales/ Income from operations (Net of Excise Duty)	884.24	1,050.83	747.93	2,725.34	1,779.82	2,454.68
b.	Other Operating Income	84.43	48.98	5.78	145.09	10.63	133.97
	Total income from operations (Net)	968.67	1,099.81	753.71	2,870.43	1,790.45	
2	Expenses						,
a.	Cost of materials Consumed	-	-	-	-	-	-
b.	Purchase of Stock in Trade	882.85	873.00	537.82	2,250.61	989.14	1,521.73
c.	Change in Inventories of Finised Goods, work-in-Progress and Stock-in-Trade	(64.31)	39.11	(43.95)	20.77	60.38	117.49
d.	Employee Benefits Expenses	60.69	73.91	101.83	223.59	294.75	418.01
е.	Depreciation and amortisation expenses	0.22	0.41	0.25	1.00	0.92	
f.	Other Expenditure	74.40		145.56	282.15	396.80	
	Total Expenses	953.85	1,105.58	741.51	2,778.12	1,741.99	2,527.17
3	Profit/ (loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	14.82	(5.77)	12.20	92.31	48.46	61.48
4	Other Income	0.20	0.30	-	0.50		3.67
5	Profit/ (Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)	15.02	(5.47)	12.20	92.81	48.46	65.15
6	Finance Cost	1.18	1.71	0.13	3.08	0.44	7.89
7	Profit/ (Loss) from ordinary activities after Finance Cost but before Exceptional Items (5+6)	13.84	(7.18)	12.07	89.73	48.02	57.26
8	Exceptional Items	41.40	-	-	41.40		-
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	(27.56)	(7.18)	12.07	48.33	48.02	57.26
10	Tax Expenses (Provisions)/Reversal	(5.28)		3.60	14.94	14.67	22.02
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9- 10)	(22.27)	(7.18)	8.47	33.40	33.35	35.24
12	Extraordinary Items (net of tax expenses)	-	-	-	-		-
13	Net Profit(+)/ Loss(-) for the period (11-12)	(22.27)	(7.18)	8.47	33.40	33.35	35.24
14	Paid-up equity share capital (Face Value of the Share is Rs.10/- each)	300.03	300.03	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	151.63	173.90	118.24	151.63	118.24	153.48
16	Earnings Per Share (EPS)	(0.74)	(0.24)	0.03	0.11	0.11	1.50

Note: The classification/ disclosure of items in the fiancial results shall be in accordance with the revised schedule VI of the Companies Act, 1956 Further to the above, profit/loss from discontinuing operations, if any, included in the above shall be disclosed with details thereof.

Information for the Quarter ended 31 December 2013							
S. No.	PARTICULARS	Quarter Ended	Quarter Ended	Quarter Ended	Nine Months ended	Nine Months ended	Year Ended
		31.12.2013	30.09.2013	31.12.2012	31.12.2013	31.12.2012	31.03.2013
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Α.	PARTICLUARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of Shares	1,564,324	1,564,324	1,618,624	1,564,324	1,618,624	1,564,324
	- Percentage of shareholding	52.14	52.14	53.95	52.14	53.95	52.14
2	Promoters and promoter group Shareholding						
a.	Pledged/Encumbered						
	- Number of Shares	-	-	-	-	-	
	- Percentage of shareholding (as a% of the total						
	shareholding of promoter and promoter group)	-			_	-	
	- Percentage of shareholding (as a % of the total Share	-	-	-	-	-	
b.	Capital of the Company Non-encumbered						
D.	- Number of Shares	1,435,976	1,435,976	1,381,676	1,435,976	1,381,676	1,435,976
	- Percentage of shareholding (as a % of the total	1,433,970	1,455,570	1,301,070	1,433,970	1,301,070	1,433,970
	shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a % of the total Share						
	Capital of the Company)	47.86	47.86	46.05	47.86	46.05	47.86

	Particulars	3 Months ended 31 December 2013
В	INVESTOR COMPLAINTS	
	Pending at the beginning of the Quarter	NIL
	Received during the Quarter	NIL
	Disposed of during the Quarter	NIL
	Remaining unresolved at the end of the Quarter	NIL

Note:

The above financial results have been taken on record by the board of the directors at their meeting held on 14.02.2014

For and on behalf of the Board